

Press Release

Daiichi Sankyo Ships “VAXZEVRIA™ Intramuscular Injection,” AstraZeneca COVID-19 Vaccine

Tokyo, Japan - (June 16, 2021) – Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) today announced that Daiichi Sankyo Biotech Co., Ltd., a subsidiary of Daiichi Sankyo (hereinafter, Daiichi Sankyo Biotech), has made its shipment of VAXZEVRIA™ Intramuscular Injection, a vaccine against novel coronavirus (development code, AZD1222; hereinafter, COVID-19 vaccine) developed by AstraZeneca K.K. (hereinafter, AstraZeneca). This shipment of the COVID-19 vaccine is to be provided to Southeast Asian countries and other regions through the Japanese Government.

Under the contract manufacture agreement of the COVID-19 vaccine that Daiichi Sankyo concluded with AstraZeneca in February 2021, Daiichi Sankyo Biotech has engaged in manufacturing the COVID-19 vaccine, including vial filling and packaging, since March of the same year.

The Japanese government has announced that it will supply 30 million doses of AstraZeneca’s COVID-19 vaccine to various countries and regions through COVAX¹ and through other means. In response to this announcement, a portion of the COVID-19 vaccine to be shipped from Daiichi Sankyo is expected to be provided to countries and regions including Southeast Asian countries through the Japanese Government.

As part of efforts towards ending the global COVID-19 pandemic, Daiichi Sankyo is striving to support regions in need of medical access through contract manufacture of the COVID-19 vaccine.

About Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical need. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit www.daiichisankyo.com.

Media Contacts:

Japan:

Masashi Kawase

Daiichi Sankyo Co., Ltd.

kawase.masashi.a2@daiichisankyo.co.jp

+81 3 6225 1126 (office)

Investor Relations Contact:

DaiichiSankyoIR@daiichisankyo.co.jp

Reference:

¹ COVAX is an international scheme led by the Gavi Vaccine Alliance, the Coalition for Epidemic Preparedness and Innovation (CEPI), and WHO to jointly purchase vaccines and distribute them to developing countries.